Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: New cyclic substituents at indole-2-carboxamide

Journal of Medicinal Chemistry

Volumn 54, Issue 6, 2011, Pages 1587-1598

  La Regina, Giuseppe ^a   Coluccia, Antonio ^a   Brancale, Andrea ^b   Piscitelli, Francesco ^a   Gatti, Valerio ^a   Maga, Giovanni ^c   Samuele, Alberta ^c   Pannecouque, Christophe ^e   Schols, Dominique ^e   Balzarini, Jan ^e   Novellino, Ettore ^d   Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 NITRO 1H INDOLE 2 CARBOXAMIDE; 5 BROMO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] N (PYRROLIDIN 1 YLMETHYL) 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] N (PYRROLIDIN 1 YLMETHYL) 1H INDOLE 2 CARBOXAMIDE; AMIDE; CARBENE; EFAVIRENZ; ETHYLENE; ETRAVIRINE; GLUTAMIC ACID; HISTIDINE; HYDROGEN; INDOLYLARYLSULFONE DERIVATIVE; LEUCINE; N BENZYL 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 1H INDOLE 2 CARBOXAMIDE; N BENZYL 5 CHLORO 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 4 FLUORO 1H INDOLE 2 CARBOXAMIDE; NEVIRAPINE; NITROGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHENYLALANINE; PROLINE; RNA DIRECTED DNA POLYMERASE; TYROSINE; UNCLASSIFIED DRUG; VALINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; INHIBITION KINETICS; MOLECULAR DOCKING; PERIPHERAL BLOOD MONONUCLEAR CELL; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; BENZOXAZINES; CELLS, CULTURED; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INDOLES; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; NEVIRAPINE; PROTEIN BINDING; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 79952792724     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101614j     Document Type: Article

References (58)

1. Barre-Sinoussi, F.; Chermann, J.; Rey, F.; Nugeyre, M.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotric retrovirus from a patient for a risk of acquired immunodeficiency syndrome (AIDS) Science 1983, 220, 868-871 (Pubitemid 13080157)
2. Gallo, R. C.; Sarin, P. S.; Gelmann, E. P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V. S.; Mann, D.; Sidhu, G. D.; Stahl, R. E.; Zolla.Pazner, S.; Leibowitch, J.; Popovic, M. Isolation of human T-cell leukemia virus in acquired mmunodeficiency syndrome (AIDS) Science 1983, 220, 865-867 (Pubitemid 13080156)
3. 2009 AIDS epidemic update.
4. Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go- J. Med. Chem. 2010, 53, 521-538
5. De Clercq, E. Highlights in the discovery of antiviral drugs: a personal retrospective J. Med. Chem. 2010, 53, 1438-1450
6. Este, J. A.; Cihlar, T. Current status and challenges of antiretroviral research and therapy Antiviral Res. 2010, 85, 25-33
7. Menéndez-Arias, L. Molecular basis of human immunodeficiency virus drug resistance: an update Antiviral Res. 2010, 85, 210-231
8. Paredes, R.; Clotet, B. Clinical management of HIV-1 resistance Antiviral Res. 2010, 85, 245-265
9. Hawkins, T. Understanding and managing the adverse effects of antiretroviral therapy Antiviral Res. 2010, 85, 201-209
10. Ceccherini-Silberstein, F.; Svicher, V.; Sing, T.; Artese, A.; Santoro, M. M.; Forbici, F.; Bertoli, A.; Alcaro, S.; Palamara, G.; d'Arminio Monforte, A.; Balzarini, J.; Antinori, A.; Lengauer, T.; Perno, C. F. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors J. Virol. 2007, 81, 11507-11519 (Pubitemid 47536121)
11. Sweeney1, Z. K.; Klumpp, K. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data Curr. Opin. Drug Discovery Dev. 2008, 11, 454-470
12. Vingerhoets, J.; Azijn, H.; Fransen, E.; De Baere, I.; Smeulders, L.; Jochmans, D.; Andries, K.; Pauwels, R.; de Bethune, M.-P. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments J. Virol. 2005, 79, 12773-12782 (Pubitemid 41433197)
13. Haubrich, R.; Gubernick, S.; Yasothan, U.; Kirkpatrick, P. Etravirine Nat. Rev. Drug Discovery 2008, 7, 287-288
14. Williams, T. A.; Ciccarone, T. M.; Saari, W. S.; Wai, J. S.; Greenlee, W. J.; Balani, S. K.; Goldman, M. E.; Theoharides, A. D. Indoles as Inhibitors of HIV Reverse Transcriptase. Eur. Pat. Appl. EP 0 530 907 A1, 1992.
15. Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Rooney, C. S.; Balani, S. K.; Condra, J. H.; Emini, E. A.; Goldman, M. E.; Greenlee, W. J.; Kauffman, L. R.; O'Brien, J. A.; Sardana, V. V.; Schleif, W. A.; Theoharides, A. D.; Anderson, P. S. 5-Chloro-3-(phenylsulfonyl)indole-2-carboxyamide: a novel non-nucleoside inhibitor of the HIV-1 reverse transcriptase J. Med. Chem. 1993, 36, 1291-1294 (Pubitemid 23159305)
16. Silvestri, R.; De Martino, G.; La Regina, G.; Artico, M.; Massa, S.; Vargiu, L.; Mura, M.; Loi, A. G.; Marceddu, T.; La Colla, P. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies J. Med. Chem. 2003, 46, 2482-2493 (Pubitemid 36637932)
17. Silvestri, R.; Artico, M.; De Martino, G.; La Regina, G.; Loddo, R.; La Colla, M.; La Colla, P. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild-type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations J. Med. Chem. 2004, 47, 3892-3896 (Pubitemid 38900354)
18. Piscitelli, F.; Coluccia, A.; Brancale, A.; La Regina, G.; Sansone, A.; Giordano, C.; Balzarini, J.; Maga, G.; Zanoli, S.; Samuele, A.; Cirilli, R.; La Torre, F.; Lavecchia, A.; Novellino, E.; Silvestri, R. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus J. Med. Chem. 2009, 52, 1922-1934
19. La Regina, G.; Coluccia, A.; Piscitelli, F.; Bergamini, A.; Sinistro, A.; Cavazza, A.; Maga, G.; Samuele, A.; Zanoli, S.; Novellino, E.; Artico, M.; Silvestri, R. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity J. Med. Chem. 2007, 50, 5034-5038 (Pubitemid 47525483)
20. Ludovici, D. W.; Kavash, R. W.; Kukla, M. J.; Ho, C. Y.; Ye, H.; De Corte, B L.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Moereels, H. E. L.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Lewi, P. J.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates part 2: diaryltriazine (DATA) analogues Bioorg. Med. Chem. Lett. 2001, 11, 2229-2234 (Pubitemid 32781672)
21. Klunder, J. M.; Hoermann, M.; Cywin, C. L.; David, E.; Brickwood, J. R.; Schwartz, R.; Barringer, K. J.; Pauletti, D.; Shih, C.-K.; Erickson, D. A.; Sorge, C. L.; Joseph, D. P.; Hattox, S. E.; Adams, J.; Grob, P. M. Novel nonnuceloside inhibitors of HIV-1 reverse transcriptase. 7. 8- Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes J. Med. Chem. 1998, 41, 2960-2971 (Pubitemid 28359931)
22. Cywin, C. L.; Klunder, J. M.; Hoermann, M.; Brickwood, J.; David, E.; Grob, P. M.; Schwartz, R.; Pauletti, D.; Barringer, K. J.; Shih, C.-K.; Sorge, C. L.; Erickson, D. A.; Hattox, S. E. Novel nonnuceloside inhibitors of HIV-1 reverse transcriptase. 7. 8-Aryloxymethyl and 8- arylthiomethydipyridodiazepinones J. Med. Chem. 1998, 41, 2972-2984 (Pubitemid 28359932)
23. Zhao, Z.; Wolkenberg, S. E.; Lu, M.; Munshi, V.; Moyer, G.; Feng, M.; Carella, A. V.; Ecto, L. T.; Gabryelski, L. J.; Lai, M.-T.; Prasad, S. G.; Yan, Y.; McGaughey, G. B.; Miller, M. D.; Lindsley, C. W.; Hartman, G. D.; Vacca, J. P.; Williams, T. M. Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) Bioorg. Med. Chem. Lett. 2008, 18, 554-559
24. Ragno, R.; Artico, M.; De Martino, G.; La Regina, G.; Coluccia, A.; Di Pasquali, A.; Silvestri, R. Docking and 3-D QSAR studies on indolyl aryl sulfones (IASs). Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N -(2-hydroxyethyl) carboxyamide and N -(2-hydroxyethyl)carboxyhydrazide derivatives J. Med. Chem. 2005, 48, 213-223 (Pubitemid 40109512)
25. De Martino, G.; La Regina, G.; Ragno, R.; Coluccia, A.; Bergamini, A.; Ciaprini, C.; Sinistro, A.; Maga, G.; Crespan, E.; Artico, M.; Silvestri., R. Indolyl aryl sulfones (IASs) as HIV-1 non-nucleoside reverse transcriptase inhibitors. Synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide Antiviral Chem. Chemother. 2006, 17, 59-77
26. Ragno, R.; Coluccia, A.; La Regina, G.; De Martino, G.; Piscitelli, F.; Lavecchia, A.; Novellino, E.; Bergamini, A.; Ciaprini, C.; Sinistro, A.; Maga, G.; Crespan, E.; Artico, M.; Silvestri, R. Design, molecular modeling, synthesis and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide J. Med. Chem. 2006, 49, 3172-3184 (Pubitemid 43830516)
27. Polinsky, A. Lead-likenss and Drug-likeness. In The Practice of Medicinal Chemistry, 3 rd ed.; Wermuth C. G. Elsevier Ltd.: Oxford, U.K., 2008; pp 244 - 254.
28. Veber, D. F.; Johnson, S. R.; Cheng, H.-C.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties influence the oral bioavilability of drug candidate J. Med. Chem. 2002, 45, 2615-2623 (Pubitemid 34595232)
29. The recombinant HIV-1 RT carrying the Y181I mutation was comparable to the Y181C substitution in terms of drug resistance, from an enzymological point of view. See ref 17.
30. Corbett, J. W.; Rodgers, J. D. Discovery of second generation of quinazoline non-nucleoside reverse transcriptase inhibitors of HIV-1 Prog. Med. Chem. 2002, 40, 63-105
31. ALOGPS and ALOGpS values were calculated at the Web site www.vcclab.org using ALOGPS version 2.1
32. Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S.; Tanchuk, V. Y.; Prokopenko, V. V. Virtual computational chemistry laboratory-design and description J. Comp. Aid Mol. Des. 2005, 19, 453-463 (Pubitemid 41613292)
33. VCCLAB, Virtual Computational Chemistry Laboratory. http://www.vcclab. org.
34. Silvestri, R.; La Regina, G.; De Martino, G.; Artico, A.; Befani, O.; Palumbo, M.; Agostinelli, E.; Turini, P. Simple, potent and selective pyrrole inhibitors of monoamine oxidase type A and type B J. Med. Chem. 2003, 46, 917-920 (Pubitemid 36423138)
35. Silvestri, R.; Artico, M.; La Regina, G.; De Martino, G.; La Colla, M.; Loddo, R.; La Colla, P. Anti-HIV-1 activity of pyrryl aryl sulfone (PAS) derivatives. Synthesis and SAR studies of novel esters and amides at the position 2 of the pyrrole nucleus Farmaco 2004, 59, 201-210 (Pubitemid 38251617)
36. Silvestri, R.; Marfa, G.; Artico, M.; La Regina, G.; De Martino, G.; Lavecchia, A.; Novellino, E.; Morgante, E.; Di Stefano, C.; Catalano, G.; Filomeni, G.; Abruzzese, E.; Ciriolo, M. R.; Russo, M. A.; Amadori, S.; Cirilli, R.; La Torre, F.; Sinibaldi Salimei, P. Pyrrolo[1,2- b ][1,2,5] benzothiadiazepines (PBTDs): a new class of agents endowed with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and imatinib-resistant J. Med. Chem. 2006, 49, 5840-5844 (Pubitemid 44423720)
37. La Regina, G.; Coluccia, A.; Silvestri, R. Looking for an active conformation of the future HIV-1 non-nucleoside reverse transcriptase inhibitors Antiviral Chem. Chemother. 2010, 20, 231-237
38. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: applications of AutoDock J. Mol. Recognit. 1996, 9, 1-5 (Pubitemid 126565462)
39. Korb, O.; Stützle, T.; Exner, T. E. PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design. In Ant Colony Optimization and Swarm Intelligence, Proceedings of the 5th International Workshop, ANTS; Dorigo, M.; Gambardella, L. M.; Birattari, M.; Martinoli, A.; Poli, R.; Stützle, T., Eds.; Lecture Notes in Computer Science, Series 4150; Springer: Berlin, 2006; pp 247 - 258. (Pubitemid 44811953)
40. FlexX version 2.2; BioSolveIT GmbH: Sankt Augustin, Germany; http://www.biosolveit.de/FlexX/.
41. Molecular Operating Environment (MOE) version 2009.10; Chemical Computing Group Inc.: Montreal, Canada; http://www.chemcomp.com/.
42. Zhao, Z.; Wolkenberg, S. E.; Lu, M.; Munshi, V.; Moyer, G.; Feng, M.; Carella, A. V.; Ecto, L. T.; Gabryelski, L. J.; Lai, M.-T.; Prasad, S. G.; Yan, Y.; McGaughey, G. B.; Miller, M. D.; Lindsley, C. W.; Hartman, G. D.; Vacca, J. P.; Williams, T. M. Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) Bioorg. Med. Chem. Lett. 2008, 18, 554-559
43. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 1992, 256, 1783-1790
44. Das, K.; Bauman, J. D.; Clark, A. D., Jr.; Frenkel, Y. V.; Lewi, P. J.; Shatkin, A. J.; Hughes, S. H.; Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations Proc. Nat. Acad. Sci. U.S.A. 2008, 105, 1466-1471 (Pubitemid 351346537)
45. Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase Structure 2000, 8, 1089-1094 (Pubitemid 32667472)
46. Ren, J.; Nichols, C. E.; Chamberlain, P. P.; Weaver, K. L.; Short, S. A.; Stammers, D. K. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors J. Mol. Biol. 2004, 336, 569-578 (Pubitemid 38183013)
47. Ren, J.; Nichols, C. E.; Chamberlain, P. P.; Weaver, K. L.; Short, S. A.; Chan, J. H.; Kleim, J. P.; Stammers, D. K. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases J. Med. Chem. 2007, 50, 2301-2309 (Pubitemid 46799242)
48. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D. I.; Stammers, D. K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors J. Mol. Biol. 2001, 312, 795-805 (Pubitemid 33116741)
49. Code "scoring.svl" was obtained from SLV Exchange Web site http://svl.chemcomp.com (Chemical Computing Group, Inc., Montreal, Canada).
50. Case, D. A; Cheatham, T. E., III; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. The Amber biomolecular simulation programs J. Comput. Chem. 2005, 26, 1668-1688 (Pubitemid 43076180)
51. Meagher, K. L.; Redman, L. T.; Carlson, H. A. Development of polyphosphate parameters for use with the AMBER force field J. Comput. Chem. 2003, 24, 1016-1026
52. Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations J. Mol. Graph. Model. 2006, 25, 247-260 (Pubitemid 44363172)
53. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general AMBER force field J. Comput. Chem. 2004, 25, 1157-1174
54. AmberTools version 1.4; http://ambermd.org/#AmberTools.
55. PyMOL version 1.2r1; DeLano Scientific LLC: San Carlos, CA http://www.pymol.org/.
56. Van Nhien, A. N.; Tomassi, C.; Len, C.; Marco-Contelles, J. L.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Postel, D. First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication J. Med. Chem. 2005, 48, 4276-4284 (Pubitemid 40884931)
57. Pannecouque, C.; Daelemans, D.; De Clercq, E. Tetrazolum-based colometric assay for the detection of HIV replication inhibitors: revised 20 years latter Nat. Protoc. 2008, 3, 427-434 (Pubitemid 351384256)
58. Maga, G.; Amacker, M.; Ruel, N.; Hubsher, U.; Spadari, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions J. Mol. Biol. 1997, 274, 738-747 (Pubitemid 28021342)